CW February 2005
Volume 14Issue Number 2 February 2005 ISSN 10593802 Phase I/II Clinical Trial of a New Antifolate in NSCLC to StartHana Biosciences, Inc. South San Francisco, CA has announced the initiation of a Phase I/II clinical trial of PT-523 as a single agent in relapsed non-small cell lung cancer (NSCLC).
Go to Previous Page Go to Next Page Source & Additional Reading R. Salgia, Director, Thoracic Oncology Research Program and Associate Professor of Medicine, University of Chicago and one of the lead investigators on the new study. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW February 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
